AGENUS INC Insider Trading Activity

AGENUS INC Chief Medical Officer Steven J. O'Day received two stock option awards covering a total of 165,333 shares of common stock.

Rhea-AI Filing Summary

AGENUS INC Chief Medical Officer Steven J. O'Day received two stock option awards covering a total of 165,333 shares of common stock. Both option grants have an exercise price of $3.90 per share and expire on April 24, 2036.

One option for 95,333 shares was awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments thereafter. A second option for 70,000 shares was granted under the same plan in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026.

Insider Trade Summary

Grant/Award: 165,333 shares

Grant/Award 2 txns

Insider O'Day Steven J

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	70,000	$0.00	$0.00
Grant/Award	Stock Option	95,333	$0.00	$0.00

Holdings After Transaction: Stock Option — 165,333 contracts (Direct)

Footnotes (2)

1. F1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.
2. F2. Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

Key Figures

Option grant size: 95,333 options Bonus replacement options: 70,000 options Total options granted: 165,333 options +4 more

7 metrics

Option grant size 95,333 options Equity Incentive Plan award vesting over three years from April 24, 2027

Bonus replacement options 70,000 options Granted in lieu of 2025 annual cash bonus, vesting May 24, 2026

Total options granted 165,333 options Combined options awarded to Steven J. O'Day on April 24, 2026

Exercise price $3.90 per share Exercise price for both Agenus stock option grants

Option expiration April 24, 2036 Expiration date for both stock option grants

Shares underlying first grant 95,333 shares Common stock underlying first option grant following transaction

Shares underlying second grant 70,000 shares Common stock underlying second option grant following transaction

Key Terms

2019 Amended and Restated Equity Incentive Plan, vests over three years, annual cash bonus, stock option, +1 more

5 terms

2019 Amended and Restated Equity Incentive Plan financial

"Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan"

vests over three years financial

"and vests over three years with one-third of the award vesting on April 24, 2027"

annual cash bonus financial

"Option awarded in lieu of the 2025 annual cash bonus"

stock option financial

"Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

underlying security financial

"underlying_security_title: "Common Stock", underlying_security_shares: "95333.0000""

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Steven J

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$3.9	04/24/2026		A		70,000		(1)	04/24/2036	Common Stock	70,000	$0.00	70,000	D
Stock Option	$3.9	04/24/2026		A		95,333		(2)	04/24/2036	Common Stock	95,333	$0.00	95,333	D

Explanation of Responses:

1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

2. Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

	/s/ Austin Charette, as Attorney-in-Fact for Steven O'Day	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)